Member Content

TCR2 Therapeutic (TCRR) a Potential Game-Changer in Solid Tumors

by Joe Kunkle | Jan 10, 2021

TCR2 Therapeutic (TCRR) was a successful small cap Biotech in 2020 with shares gaining around 100% and will be presenting at the JP Morgan Healthcare Conference this week on 1-14-.
TCRR is a clinical-stage immunotherapy company developing the next ge...

Please login to continue reading this article.

Options Hawk Max

$399 | 30 days

Options Hawk Trading Hub Live Chat
Hawk’s Market Blitz
Spotlight Trades (2 Per Week)
Market Recap
Weekly Earnings Snapshots
Live Mock Portfolio
1 on 1 Access
Hawk’s Trader Toolbox
Street Research
OptionsHawk Research
Daily Options Radar
OptionHawk’s Weekly Radar Report
Options Hawk Market Outlook Access
Daily Earnings Grid
Weekly and Monthly OpEx Sheets
Notable Options Database
OptionsHawk Quarterly Market Brief

More About this Plan

Options Hawk Elite

$199 | 30 days

Hawk’s Market Blitz
Spotlight Trades (2 Per Week)
Market Recap
Weekly Earnings Snapshots
OptionsHawk Research
Daily Options Radar
OptionHawk’s Weekly Radar Report
Options Hawk Market Outlook Access
Daily Earnings Grid
OptionsHawk Quarterly Market Brief

More About this Plan